These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8274744)

  • 1. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination.
    Cavazzana-Calvo M; Stephan JL; Sarnacki S; Chevret S; Fromont C; de Coene C; Le Deist F; Guy-Grand D; Fischer A
    Blood; 1994 Jan; 83(1):288-98. PubMed ID: 8274744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
    J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
    Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
    Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
    Pierce GE
    Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
    Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
    Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.
    Blazar BR; Carroll SF; Vallera DA
    Blood; 1991 Dec; 78(11):3093-102. PubMed ID: 1954395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
    Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
    Sefrioui H; Billiau AD; Waer M
    Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.
    Martin PJ
    Blood; 1996 Aug; 88(3):962-9. PubMed ID: 8704255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
    Blazar BR; Taylor PA; Smith S; Vallera DA
    Blood; 1995 Feb; 85(3):842-51. PubMed ID: 7833486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
    Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
    Martin PJ
    J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
    Amrolia PJ; Muccioli-Casadei G; Yvon E; Huls H; Sili U; Wieder ED; Bollard C; Michalek J; Ghetie V; Heslop HE; Molldrem JJ; Rooney CM; Schlinder J; Vitetta E; Brenner MK
    Blood; 2003 Sep; 102(6):2292-9. PubMed ID: 12763937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR; Majewski D
    Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.
    Chen BJ; Cui X; Liu C; Chao NJ
    Blood; 2002 May; 99(9):3083-8. PubMed ID: 11964269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.